Wang J - Search Results

1

Novel small molecule inhibitors targeting renal cell carcinoma: Status, challenges, future directions.

Xiong L, Zhang Y, Wang J, Yu M, Huang L, Hou Y, Li G, Wang L, Li Y. Xiong L, et al. Among authors: wang l, wang j. Eur J Med Chem. 2024 Mar 5;267:116158. doi: 10.1016/j.ejmech.2024.116158. Epub 2024 Jan 17. Eur J Med Chem. 2024. PMID: 38278080 Free article. Review.

2

DYRK1A inhibitors for disease therapy: Current status and perspectives.

Liu T, Wang Y, Wang J, Ren C, Chen H, Zhang J. Liu T, et al. Among authors: wang j, wang y. Eur J Med Chem. 2022 Feb 5;229:114062. doi: 10.1016/j.ejmech.2021.114062. Epub 2021 Dec 21. Eur J Med Chem. 2022. PMID: 34954592 Review.

3

Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities.

Hu X, Zhang J, Zhang Y, Jiao F, Wang J, Chen H, Ouyang L, Wang Y. Hu X, et al. Among authors: wang j, wang y. Eur J Med Chem. 2022 Feb 15;230:114094. doi: 10.1016/j.ejmech.2021.114094. Epub 2021 Dec 30. Eur J Med Chem. 2022. PMID: 34998039 Review.

4

Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.

Zhang L, Zhang J, Wang J, Ren C, Tang P, Ouyang L, Wang Y. Zhang L, et al. Among authors: wang j, wang y. Eur J Med Chem. 2022 Mar 15;232:114176. doi: 10.1016/j.ejmech.2022.114176. Epub 2022 Feb 3. Eur J Med Chem. 2022. PMID: 35151222 Review.

5

Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.

Chen J, Tang P, Wang Y, Wang J, Yang C, Li Y, Yang G, Wu F, Zhang J, Ouyang L. Chen J, et al. Among authors: wang j, wang y. J Med Chem. 2022 Apr 14;65(7):5184-5211. doi: 10.1021/acs.jmedchem.1c01835. Epub 2022 Mar 24. J Med Chem. 2022. PMID: 35324195

6

Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity.

Wei J, Wang J, Zhang J, Yang J, Wang G, Wang Y. Wei J, et al. Among authors: wang g, wang j, wang y. Eur J Med Chem. 2022 Jun 5;236:114301. doi: 10.1016/j.ejmech.2022.114301. Epub 2022 Mar 31. Eur J Med Chem. 2022. PMID: 35390715 Review.

7

Targeting EZH2 for cancer therapy: From current progress to novel strategies.

Zeng J, Zhang J, Sun Y, Wang J, Ren C, Banerjee S, Ouyang L, Wang Y. Zeng J, et al. Among authors: wang j, wang y. Eur J Med Chem. 2022 Aug 5;238:114419. doi: 10.1016/j.ejmech.2022.114419. Epub 2022 Apr 30. Eur J Med Chem. 2022. PMID: 35569264 Review.

8

Current progress and novel strategies that target CDK12 for drug discovery.

Lei P, Zhang J, Liao P, Ren C, Wang J, Wang Y. Lei P, et al. Among authors: wang j, wang y. Eur J Med Chem. 2022 Oct 5;240:114603. doi: 10.1016/j.ejmech.2022.114603. Epub 2022 Jul 12. Eur J Med Chem. 2022. PMID: 35868123 Review.

9

Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.

Zhou Z, Zhang J, Zhou E, Ren C, Wang J, Wang Y. Zhou Z, et al. Among authors: wang j, wang y. Eur J Med Chem. 2022 Oct 5;240:114595. doi: 10.1016/j.ejmech.2022.114595. Epub 2022 Jul 8. Eur J Med Chem. 2022. PMID: 35868125 Review.

10

Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential.

Zhang J, Zhang L, Wang J, Ouyang L, Wang Y. Zhang J, et al. Among authors: wang j, wang y. J Med Chem. 2022 Aug 11;65(15):10133-10160. doi: 10.1021/acs.jmedchem.2c00614. Epub 2022 Jul 25. J Med Chem. 2022. PMID: 35878418 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217,629 results

Search Page

Filters